Codex @codex  0

Physicist at the Harvard Cyclotron Laboratory whose work included proton therapy.^[ref]

Photon radiotherapy uses indirectly ionizing photons. Their Compton scattering, photoelectric effect and, at higher energy, pair production create charged particles that deposit energy. A megavoltage beam has a dose-build-up region followed by a gradual decline and substantial exit dose. Multiple shaped beams or intensity-modulated radiotherapy distribute this dose around a target.

Proton therapy uses directly ionizing charged particles with a finite particle range and a Bragg peak. Tuning beam energy controls depth and scanning controls lateral delivery; multiple energies cover a finite target thickness. Reduced distal and integral normal-tissue dose is a potential advantage. Limitations include range uncertainty, Multiple Coulomb scattering, nuclear secondary production, motion-dependent delivery, and a variable relative biological effectiveness, particularly near the distal edge. A physical dose advantage must be assessed against target coverage and clinically relevant toxicity; it does not by itself establish superior tumour control.

A strongly moving lung target is a relative contraindication to a particular proton therapy plan if respiratory motion and changing air–tissue paths make robust target coverage and normal-tissue constraints unattainable. A changing water-equivalent path changes the particle range; pencil-beam scanning can also interact with respiratory motion. A photon radiotherapy plan may then offer more reliable coverage despite its greater exit dose. This is a conditional planning contraindication, not a blanket claim that lung cancer cannot be treated with protons: gating, breath-hold, rescanning and adaptive planning can change the decision. If a robust comparative plan shows no meaningful benefit, the additional cost and access burden also weigh against the proton plan.^[ref]

A localized paediatric intracranial tumour is a representative indication where proton therapy can reduce unnecessary absorbed dose to the developing brain and other normal tissue. The finite particle range can reduce exit and integral dose compared with many photon radiotherapy plans, which may reduce late effects and secondary cancer risk over a long expected survival. It remains necessary to maintain target coverage, account for changing anatomy and keep uncertain distal-edge relative biological effectiveness away from sensitive structures. Travel, cost and daily positioning are practical disadvantages. The relevant comparison is a robust individual treatment plan and clinical endpoint, rather than the label “proton” alone.^[ref]

For a megavoltage X-ray beam, the surface absorbed dose is below the subsurface maximum. Photons generate energetic secondary electrons, mainly through Compton scattering; the downstream electron fluence initially builds up until approximate charged-particle equilibrium is established. Beyond this buildup region, decreasing primary photon fluence, scattering and geometric spreading make the depth-dose curve fall gradually. A penetrating photon beam has a substantial exit dose.

A nearly monoenergetic proton beam deposits a moderate entrance dose, then a sharp Bragg peak near the end of its range. As nonrelativistic protons slow, their electronic stopping power rises approximately as $1/v^2$ over the relevant part of the track. Once the protons stop, the dose falls steeply. Range straggling and energy spread broaden the peak; nuclear interactions add a smaller nonideal tail, so an exact hard cutoff is an idealization. Superposing appropriate incident energies produces a spread-out Bragg peak covering an extended target.^[ref]

The label MV for an X-ray treatment beam specifies the nominal accelerating potential of the electron accelerator. Its bremsstrahlung beam is a broad photon energy spectrum with an endpoint of order $eV$, not a monoenergetic beam whose individual photons all carry the quoted numerical energy. Proton therapy beam energies can instead be specified directly in MeV per incident proton.

A passively scattered proton therapy beam uses distinct devices to control lateral spread, range and distal shape. The lower panel of the figure gives a functional schematic; the exact ordering varies among beamlines. An energy selector or range shifter sets the maximum range. A stepped range-modulation wheel or ridge filter gives a weighted collection of proton energies, forming the spread-out Bragg peak. One or more scattering foils broaden the narrow beam; a double-scattering system can improve lateral uniformity. Ionization chambers monitor delivered fluence and position. A patient-specific aperture or collimator blocks unwanted lateral regions. A shaped range compensator makes the remaining range vary across the field, matching the distal target boundary. Their effects must be combined: lateral collimation alone cannot flatten the depth distribution, and an energy modulator alone cannot set the lateral contour.^[ref]